The role of the liver X receptor in chronic obstructive pulmonary disease

Respiratory Research

Dave Singh²  David Ray²  Karen Simpson¹  Barbara Maschera¹  Jonathan Plumb²  Simon Lea²  Andrew Higham² 

[1] GlaxoSmithKline, Respiratory CEDD, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK;The University of Manchester, NIHR Translational Research Facility, University Hospital of South Manchester Foundation Trust, Southmoor Road, Manchester M23 9LT, UK

关键词: Inflammatory cytokines;    Alveolar macrophage;    Liver X receptor;    COPD;   

Others  :  792596
DOI  :  10.1186/1465-9921-14-106

 received in 2013-06-24, accepted in 2013-09-25,  发布年份 2013

【 摘 要 】

Background

There is a need for novel anti-inflammatory therapies to treat COPD. The liver X receptor (LXR) is a nuclear hormone receptor with anti-inflammatory properties.

Methods

We investigated LXR gene and protein expression levels in alveolar macrophages and whole lung tissue from COPD patients and controls, the effect of LXR activation on the suppression of inflammatory mediators from LPS stimulated COPD alveolar macrophages, and the effect of LXR activation on the induction of genes associated with alternative macrophage polarisation.

Results

The levels of LXR mRNA were significantly increased in whole lung tissue extracts in COPD patients and smokers compared to non-smokers. The expression of LXR protein was significantly increased in small airway epithelium and alveolar epithelium in COPD patients compared to controls. No differences in LXR mRNA and protein levels were observed in alveolar macrophages between patient groups. The LXR agonist GW3965 significantly induced the expression of the LXR dependent genes ABCA1 and ABCG1 in alveolar macrophage cultures. In LPS stimulated alveolar macrophages, GW3965 suppressed the production of CXCL10 and CCL5, whilst stimulating IL-10 production.

Conclusions

GW3965 did not significantly suppress the production of TNFα, IL-1β, or CXCL8. Our major finding is that LXR activation has anti-inflammatory effects on CXC10, CCL5 and IL-10 production from alveolar macrophages.

【 授权许可】

   
2013 Higham et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]van der Vaart H, Postma DS, Timens W, ten Hacken NH: Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 2004, 59:713-721.
• [2]Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.com webcite
• [3]Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, Mapp CE, Fabbri LM, Donner CF, Saetta M: Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998, 158:1277-1285.
• [4]Barnes PJ: Alveolar macrophages as orchestrators of COPD. Copd 2004, 1:59-70.
• [5]Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ: LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 1995, 9:1033-1045.
• [6]Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ: Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93:693-704.
• [7]Sabol SL, Brewer HB Jr, Santamarina-Fojo S: The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver. J Lipid Res 2005, 46:2151-2167.
• [8]Schwartz K, Lawn RM, Wade DP: ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun 2000, 274:794-802.
• [9]Costet P, Luo Y, Wang N, Tall AR: Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 2000, 275:28240-28245.
• [10]Zelcer N, Hong C, Boyadjian R, Tontonoz P: LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325:100-104.
• [11]Calkin AC, Tontonoz P: Liver x receptor signaling pathways and atherosclerosis. Arterioscler, Thromb, Vasc Biol 2010, 30:1513-1518.
• [12]Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, et al.: Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002, 99:7604-7609.
• [13]Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P: Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003, 9:213-219.
• [14]Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, Hoffmann A, Subramaniam S, David M, Rosenfeld MG, Glass CK: Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122:707-721.
• [15]Walcher D, Kummel A, Kehrle B, Bach H, Grub M, Durst R, Hombach V, Marx N: LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes. Arterioscler, Thromb, Vasc Biol 2006, 26:1022-1028.
• [16]Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, Willson TM, Rosenfeld MG, Glass CK: Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell 2007, 25:57-70.
• [17]Lee JH, Park SM, Kim OS, Lee CS, Woo JH, Park SJ, Joe EH, Jou I: Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes. Mol Cell 2009, 35:806-817.
• [18]Birrell MA, Catley MC, Hardaker E, Wong S, Willson TM, McCluskie K, Leonard T, Farrow SN, Collins JL, Haj-Yahia S, Belvisi MG: Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses. J Biol Chem 2007, 282:31882-31890.
• [19]Shaykhiev R, Krause A, Salit J, Strulovici-Barel Y, Harvey BG, O'Connor TP, Crystal RG: Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol 2009, 183:2867-2883.
• [20]Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P: Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000, 97:12097-12102.
• [21]Pradel LC, Mitchell AJ, Zarubica A, Dufort L, Chasson L, Naquet P, Broccardo C, Chimini G: ATP-binding cassette transporter hallmarks tissue macrophages and modulates cytokine-triggered polarization programs. Eur J Immunol 2009, 39:2270-2280.
• [22]Armstrong J, Sargent C, Singh D: Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. Clinical and experimental immunology 2009, 158:74-83.
• [23]Schulz C, Farkas L, Wolf K, Kratzel K, Eissner G, Pfeifer M: Differences in LPS-induced activation of bronchial epithelial cells (BEAS-2B) and type II-like pneumocytes (A-549). Scand J Immunol 2002, 56:294-302.
• [24]Lam KP, Chu YT, Lee MS, Chen HN, Wang WL, Tok TS, Chin YY, Chen SC, Kuo CH, Hung CH: Inhibitory effects of albuterol and fenoterol on RANTES and IP-10 expression in bronchial epithelial cells. Pediatr Allergy Immunol 2011, 22:431-439.
• [25]Plumb J, Smyth LJ, Adams HR, Vestbo J, Bentley A, Singh SD: Increased T-regulatory cells within lymphocyte follicles in moderate COPD. Eur Respir J 2009, 34:89-94.
• [26]Ohmori Y, Hamilton TA: Requirement for STAT1 in LPS-induced gene expression in macrophages. J Leukoc Biol 2001, 69:598-604.
• [27]Li N, Salter RC, Ramji DP: Molecular mechanisms underlying the inhibition of IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J Cell Biochem 2011, 112:675-683.
• [28]Kovarik P, Stoiber D, Novy M, Decker T: Stat1 combines signals derived from IFN-gamma and LPS receptors during macrophage activation. EMBO J 1998, 17:3660-3668.
• [29]Fontaine C, Rigamonti E, Nohara A, Gervois P, Teissier E, Fruchart JC, Staels B, Chinetti-Gbaguidi G: Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ Res 2007, 101:40-49.
• [30]Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S, Bellettato CM, Papi A, Corbetta L, Zuin R, et al.: Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 165:1404-1409.
• [31]Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
• [32]Kelsen SG, Aksoy MO, Georgy M, Hershman R, Ji R, Li X, Hurford M, Solomides C, Chatila W, Kim V: Lymphoid follicle cells in chronic obstructive pulmonary disease overexpress the chemokine receptor CXCR3. Am J Respir Crit Care Med 2009, 179:799-805.
• [33]Guo JJ, Li QL, Zhang J, Huang AL: Histone deacetylation is involved in activation of CXCL10 upon IFNgamma stimulation. Mol Cells 2006, 22:163-167.
• [34]Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P: Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol 2001, 21:7558-7568.
• [35]Whitney KD, Watson MA, Goodwin B, Galardi CM, Maglich JM, Wilson JG, Willson TM, Collins JL, Kliewer SA: Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. J Biol Chem 2001, 276:43509-43515.
• [36]Sugiura H, Koarai A, Ichikawa T, Minakata Y, Matsunaga K, Hirano T, Akamatsu K, Yanagisawa S, Furusawa M, Uno Y, et al.: Increased 25-hydroxycholesterol concentrations in the lungs of patients with chronic obstructive pulmonary disease. Respirology 2012, 17:533-540.
• [37]Kikuchi T, Sugiura H, Koarai A, Ichikawa T, Minakata Y, Matsunaga K, Nakanishi M, Hirano T, Akamatsu K, Yanagisawa S, et al.: Increase of 27-hydroxycholesterol in the airways of patients with chronic obstructive pulmonary disease: possible role of 27-hydroxycholesterol in tissue fibrosis. Chest 2012, 142:329-337.
• [38]Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, et al.: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7:53-58.
• [39]Ozasa H, Ayaori M, Iizuka M, Terao Y, Uto-Kondo H, Yakushiji E, Takiguchi S, Nakaya K, Hisada T, Uehara Y, et al.: Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARgamma/LXRalpha pathway: findings from in vitro and ex vivo studies. Atherosclerosis 2011, 219:141-150.
• [40]Sticozzi C, Pecorelli A, Belmonte G, Valacchi G: Cigarette Smoke Affects ABCAl Expression via Liver X Receptor Nuclear Translocation in Human Keratinocytes. Int J Mol Sci 2010, 11:3375-3386.
• [41]Hodge G, Nairn J, Holmes M, Reynolds PN, Hodge S: Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects. Clinical and experimental immunology 2007, 150:22-29.
• [42]Majori M, Corradi M, Caminati A, Cacciani G, Bertacco S, Pesci A: Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. The Journal of allergy and clinical immunology 1999, 103:458-462.
• [43]Landis MS, Patel HV, Capone JP: Oxysterol activators of liver X receptor and 9-cis-retinoic acid promote sequential steps in the synthesis and secretion of tumor necrosis factor-alpha from human monocytes. J Biol Chem 2002, 277:4713-4721.
• [44]Birrell MA, De Alba J, Catley MC, Hardaker E, Wong S, Collins M, Clarke DL, Farrow SN, Willson TM, Collins JL, Belvisi MG: Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth. J Immunol 2008, 181:4265-4271.
• [45]Asquith DL, Miller AM, Hueber AJ, McKinnon HJ, Sattar N, Graham GJ, McInnes IB: Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis. Arthritis Rheum 2009, 60:2655-2665.
• [46]Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett KA, Singh D: Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2011, 338:732-740.
• [47]Southworth T, Metryka A, Lea S, Farrow S, Plumb J, Singh D: IFNgamma synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid resistant STAT1 activation. Br J Pharmacol 2012, 166:2070-2083.